Abstract | INTRODUCTION: The positive results of pioneering clinical trials using gene therapy as treatment for patients with Leber congenital amaurosis (LCA) have ushered in a new era of molecular retinal therapeutics for LCA, other blinding retinal disorders and gene therapy applications. AREAS COVERED: This review describes the role of retinal pigment epithelium-specific 65 kDa protein (RPE65) in the visual cycle and how RPE65 deficiency results in LCA; the extensive preclinical studies with recombinant adeno-associated virus (rAAV)-RPE65 gene vectors; and the human rAAV-RPE65 and related gene therapy clinical trials and studies. The literature search included a review of primary sources (e.g., journal articles) that reported study data results and key secondary sources such as meta-reviews available through PubMed, as well as reviews of clinical trial descriptions and results as reported in clinicaltrials.gov, conference publications and news releases. EXPERT OPINION: LCA-RPE65 gene therapy is an example of successful, innovative, translational research. Further research is needed regarding how retinal gene therapy can be improved.
|
Authors | Linda Stein, Kamolika Roy, Lei Lei, Shalesh Kaushal |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 11
Issue 3
Pg. 429-39
(Mar 2011)
ISSN: 1744-7682 [Electronic] England |
PMID | 21299439
(Publication Type: Journal Article, Review)
|
Chemical References |
- Carrier Proteins
- Eye Proteins
- retinoid isomerohydrolase
- cis-trans-Isomerases
|
Topics |
- Animals
- Carrier Proteins
(genetics, metabolism)
- Dependovirus
(genetics)
- Evidence-Based Medicine
- Eye Proteins
(genetics, metabolism)
- Gene Transfer Techniques
- Genetic Therapy
(adverse effects)
- Genetic Vectors
- Humans
- Leber Congenital Amaurosis
(genetics, metabolism, physiopathology, therapy)
- Retina
(metabolism, physiopathology)
- Translational Research, Biomedical
- Treatment Outcome
- Vision, Ocular
- cis-trans-Isomerases
|